The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

PROCATEROL     8-hydroxy-5-[1-hydroxy-2- (propan-2...

Synonyms: Meptin, Procaterolo, Procaterolum, SureCN4632, CHEMBL160519, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PROCATEROL

  • A placebo-controlled trial of procaterol: a new long-acting oral beta 2-agonist in bronchial asthma [1].
  • BACKGROUND--To evaluate the effect of inhaled beta 2 adrenergic agonists on the sensitivity of airway cough receptors, the effect of inhaled procaterol on cough induced by aerosolised capsaicin, a stimulant of C fibres, was studied in patients with asthma or chronic bronchitis and in normal subjects [2].
  • When coronary stenosis was absent, intracoronary infusion of procaterol (6.7 ng/min for 15 min) produced significant increases in LCX flow and myocardial segment shortening in the infused region without changes in global hemodynamics [3].
  • Cardiac effects of beta-2 adrenoceptor stimulation with intracoronary procaterol in the absence and presence of regional myocardial ischemia in dogs [3].
  • Procaterol (10 and 30 ng kg-1 min-1, i.v.) also produced hypotension but did not alter pressor responses to sympathetic nerve stimulation [4].

High impact information on PROCATEROL


Chemical compound and disease context of PROCATEROL


Biological context of PROCATEROL


Anatomical context of PROCATEROL


Associations of PROCATEROL with other chemical compounds


Gene context of PROCATEROL


Analytical, diagnostic and therapeutic context of PROCATEROL


  1. A placebo-controlled trial of procaterol: a new long-acting oral beta 2-agonist in bronchial asthma. Siegel, S.C., Katz, R.M., Rachelefsky, G.S., Brandon, M.L., Borgen, L.A. J. Allergy Clin. Immunol. (1985) [Pubmed]
  2. Effect of inhaled procaterol on cough receptor sensitivity to capsaicin in patients with asthma or chronic bronchitis and in normal subjects. Fujimura, M., Sakamoto, S., Kamio, Y., Bando, T., Kurashima, K., Matsuda, T. Thorax (1993) [Pubmed]
  3. Cardiac effects of beta-2 adrenoceptor stimulation with intracoronary procaterol in the absence and presence of regional myocardial ischemia in dogs. Noguchi, K., Ojiri, Y., Chibana, T., Moromizato, H., Sakanashi, M. J. Pharmacol. Exp. Ther. (1991) [Pubmed]
  4. Facilitation by procaterol, a beta-adrenoceptor agonist, of noradrenaline release in the pithed rat independently of angiotensin II formation. Kotsonis, P., Majewski, H. Br. J. Pharmacol. (1994) [Pubmed]
  5. Agonist-induced desensitization of beta-adrenoceptor function in humans. Subtype-selective reduction in beta 1- or beta 2-adrenoceptor-mediated physiological effects by xamoterol or procaterol. Brodde, O.E., Daul, A., Michel-Reher, M., Boomsma, F., Man in 't Veld, A.J., Schlieper, P., Michel, M.C. Circulation (1990) [Pubmed]
  6. Beta-Adrenoceptor-medicated down-regulation of M2 muscarinic receptors: role of cyclic adenosine 5'-monophosphate-dependent protein kinase and protein kinase C. Rousell, J., Haddad, E.B., Mak, J.C., Webb, B.L., Giembycz, M.A., Barnes, P.J. Mol. Pharmacol. (1996) [Pubmed]
  7. Angiotensin-converting enzyme inhibitor and danazol increase sensitivity of cough reflex in female guinea pigs. Ebihara, T., Sekizawa, K., Ohrui, T., Nakazawa, H., Sasaki, H. Am. J. Respir. Crit. Care Med. (1996) [Pubmed]
  8. Role of substance P in cough during bronchoconstriction in awake guinea pigs. Sekizawa, K., Ebihara, T., Sasaki, H. Am. J. Respir. Crit. Care Med. (1995) [Pubmed]
  9. Inhaled procaterol versus salbutamol in bronchial asthma. Liippo, K., Silvasti, M., Tukiainen, H. Eur. J. Clin. Pharmacol. (1991) [Pubmed]
  10. Effect of inhaled procaterol hydrochloride in children with bronchial asthma, with particular reference to duration of effect. Mitsuhashi, M., Kimura, T., Tateno, K., Morikawa, A., Kuroume, T. The Journal of asthma : official journal of the Association for the Care of Asthma. (1985) [Pubmed]
  11. Preventive effect and duration of action of disodium cromoglycate and procaterol on exercise-induced asthma in asthmatic children. Obata, T., Matsuda, S., Akasawa, A., Iikura, Y. Annals of allergy. (1993) [Pubmed]
  12. Pharmacodynamic study of procaterol hydrochloride dry powder inhaler: evaluation of pharmacodynamic equivalence between procaterol hydrochloride dry powder inhaler and procaterol hydrochloride metered-dose inhaler in asthma patients in a randomized, double-dummy, double-blind crossover manner. Kawai, M., Sakai, A., Takaori, S., Hiura, A., Sakata, N., Nakashima, M., Miyamoto, T. Methods and findings in experimental and clinical pharmacology. (2005) [Pubmed]
  13. Maximum bronchodilator effect of pirbuterol and procaterol administered as sprays with and without an aerochamber. Solé, D., Villalba, S.R., Sestelo, M.R., Scalabrin, D.M., Soares, F.J., Naspitz, C.K. Revista paulista de medicina. (1993) [Pubmed]
  14. Changes in pulmonary function and cross-sectional area of trachea and bronchi in asthmatics following inhalation of procaterol hydrochloride and ipratropium bromide. Hoffstein, V., Zamel, N., McClean, P., Chapman, K.R. Am. J. Respir. Crit. Care Med. (1994) [Pubmed]
  15. Evaluation of tremor and efficacy of oral procaterol in adult patients with asthma. Tinkelman, D.G., DeJong, R., Lutz, C., Spangler, D.L. J. Allergy Clin. Immunol. (1990) [Pubmed]
  16. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. Kaidoh, K., Igawa, Y., Takeda, H., Yamazaki, Y., Akahane, S., Miyata, H., Ajisawa, Y., Nishizawa, O., Andersson, K.E. J. Urol. (2002) [Pubmed]
  17. Lipomobilizing effects of procaterol and yohimbine in the conscious dog: comparison of endocrinological, metabolic and cardiovascular effects. Valet, P., Taouis, M., Tran, M.A., Montastruc, P., Lafontan, M., Berlan, M. Br. J. Pharmacol. (1989) [Pubmed]
  18. erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol. Tamura, Y., Yoshizaki, S., Watanabe, K. J. Med. Chem. (1981) [Pubmed]
  19. Relaxing actions of procaterol, a beta 2-adrenoceptor stimulant, on smooth muscle cells of the dog trachea. Fujiwara, T., Sumimoto, K., Itoh, T., Suzuki, H., Kuriyama, H. Br. J. Pharmacol. (1988) [Pubmed]
  20. Responses to the beta 2-selective agonist procaterol of vascular and atrial preparations with different functional beta-adrenoceptor populations. O'Donnell, S.R., Wanstall, J.C. Br. J. Pharmacol. (1985) [Pubmed]
  21. Existence of a beta3-adrenoceptro and its functional role in the human ureter. Park, Y.C., Tomiyama, Y., Hayakawa, K., Akahane, M., Ajisawa, Y., Miyatake, R., Kiwamoto, H., Sugiyama, T., Kurita, T. J. Urol. (2000) [Pubmed]
  22. Beta2-adrenergic receptor antagonist accelerates skin barrier recovery and reduces epidermal hyperplasia induced by barrier disruption. Denda, M., Fuziwara, S., Inoue, K. J. Invest. Dermatol. (2003) [Pubmed]
  23. Vascular alpha-1 antagonistic and agonistic effects of beta adrenoceptor agonists in rabbit common carotid arteries. Fujiwara, T., Chiba, S. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  24. Involvement of the locus coeruleus in the potentiation of the quipazine-induced head-twitch response by diazepam and beta-adrenoceptor agonists. Handley, S.L., Singh, L. Neuropharmacology (1986) [Pubmed]
  25. Effects of vasoconstrictive and vasodilative agents on lymphatic smooth muscles in isolated canine thoracic ducts. Takahashi, N., Kawai, Y., Ohhashi, T. J. Pharmacol. Exp. Ther. (1990) [Pubmed]
  26. Differential regulation of fat cell beta-2 and beta-1 adrenoceptors by endogenous catecholamines in dog. Valet, P., Montastruc, J.L., Berlan, M., Tran, M.A., Lafontan, M., Montastruc, P. J. Pharmacol. Exp. Ther. (1989) [Pubmed]
  27. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Igawa, Y., Yamazaki, Y., Takeda, H., Hayakawa, K., Akahane, M., Ajisawa, Y., Yoneyama, T., Nishizawa, O., Andersson, K.E. Br. J. Pharmacol. (1999) [Pubmed]
  28. Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Yoshimura, T., Kurita, C., Nagao, T., Usami, E., Nakao, T., Watanabe, S., Kobayashi, J., Yamazaki, F., Tanaka, H., Inagaki, N., Nagai, H. Pharmacology (1997) [Pubmed]
  29. Differential effects of opioid and adrenergic agonists on proliferation in a cultured cell line. Agarwal, D., Glasel, J.A. Cell Prolif. (1999) [Pubmed]
  30. Procaterol inhibits IL-1beta- and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity. Koyama, S., Sato, E., Masubuchi, T., Takamizawa, A., Kubo, K., Nagai, S., Isumi, T. Eur. Respir. J. (1999) [Pubmed]
  31. Inhibitory effect of inhaled procaterol on anaphylactic bronchoconstriction and thromboxane A2 production in guinea-pigs. Fujimura, M., Sakamoto, S., Nishi, K., Saito, M., Miyake, Y., Matsuda, T. Clin. Exp. Allergy (1991) [Pubmed]
  32. Clinical pharmacokinetics and relative bioavailability of oral procaterol. Eldon, M.A., Battle, M.M., Coon, M.J., Nordblom, G.D., Sedman, A.J., Colburn, W.A. Pharm. Res. (1993) [Pubmed]
  33. Probable involvement of vascular angiotensin II formation in the beta 2-adrenoceptor-mediated facilitation of the neurogenic vasopressor response in the pithed rat. Schlicker, E., Erkens, K., Göthert, M. Naunyn Schmiedebergs Arch. Pharmacol. (1988) [Pubmed]
WikiGenes - Universities